BARDA’s Draft New Vaccine Platforms RPP Signals a Major Push for Adaptable Medical Countermeasures
Updated to reflect Draft Version 2, issued September 24, 2026. The revised draft expands eligible pathogen targets, clarifies platform maturity requirements, and adds a preference for U.S.-based companies and domestic performance. Requirements remain subject to change in the final RPP. The Biomedical Advanced Research and Development Authority (BARDA) has released the draft Request for Project